Dosing Colistimethate Every 8 h Results in Higher Plasma Concentrations of Active Colistin Than Every 12-Hourly Dosing without Increase in Nephrotoxicity: A Phase 1 Pharmacokinetics Trial in Healthy Adult Volunteers

• Main Authors: George A. Yendewa (Author), John McLeod Griffiss (Author), Wesley A. Gray (Author), Amanda Healen (Author), Howard M. Proskin (Author), Scott A. Fulton (Author), Mary Ann O'Riordan (Author), Charles Hoppel (Author), Jeffrey L. Blumer (Author), Robert A. Salata (Author)
• Format: Book
• Published: MDPI AG, 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Despite its use for decades, pharmacokinetic (PK) and safety studies on colistin are limited. We conducted a phase l, open-label trial to evaluate the safety and PK of multiple doses of intravenous (IV) and aerosolized colistimethate sodium (CMS) administered separately and in combination. In total,...